Savara to Present at JMP Securities 2018 Life Sciences Conference on June 20th
June 13 2018 - 8:00AM
Savara Inc. (NASDAQ:SVRA), an orphan lung disease company,
announced today that the company's Chief Executive Officer, Rob
Neville, will present at the JMP Securities 2018 Life Sciences
Conference on Wednesday June 20, 2018 at 3:30 p.m. Eastern Time in
the Versailles Salon at the St. Regis Hotel in New York.
Interested parties can access a live audio webcast on the Savara
website at www.savarapharma.com. An archived presentation will be
available on the website for 30 days.
About Savara Savara is an
orphan lung disease company. Savara's pipeline comprises:
Molgradex, an inhaled granulocyte-macrophage colony-stimulating
factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary
alveolar proteinosis, or aPAP and in Phase 2a development for
nontuberculous mycobacteria, or NTM lung infection; and AeroVanc, a
Phase 3 stage inhaled vancomycin for treatment of MRSA lung
infection in cystic fibrosis, or CF. Savara's strategy involves
expanding its pipeline of potentially best-in-class products
through indication expansion, strategic development partnerships
and product acquisitions, with the goal of becoming a leading
company in its field. Savara's management team has significant
experience in orphan drug development and pulmonary medicine,
identifying unmet needs, developing and acquiring new product
candidates, and effectively advancing them to approvals and
commercialization. More information can be found at
www.savarapharma.com. (Twitter: @SavaraPharma)
Savara may announce material information about
its finances, product candidates, clinical trials and other matters
to its investors using its investor relations website
(http://savarapharma.com/investors), SEC filings, press releases,
public conference calls and webcasts. Savara uses these
channels, as well as social media, to communicate with its
stockholders and the public about the company and other issues. It
is possible that the information Savara posts on its website and
social media could be deemed to be material information. Therefore,
Savara encourages investors, the media, and others interested in
the company to review the information Savara posts on its investor
relations website (referenced above) and any social media channels
listed on its website from time to time.
Contacts:
Savara: Ioana C. Hone (ir@savarapharma.com) (512) 961-1891
For IR: Solebury Trout Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
For Media: Neon InteractivePatrick Wallace
(patrick@neoninteractive.com) (619) 200-7856
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Apr 2023 to Apr 2024